Prosecution Insights
Last updated: April 19, 2026
Application No. 17/785,184

UNNATURAL AMINO ACIDS AND USES THEREOF

Final Rejection §102
Filed
Jun 14, 2022
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Temple University-Of The Commonwealth System Of Higher Education
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
2y 0m
To Grant
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1331 granted / 1581 resolved
+24.2% vs TC avg
Moderate +10% lift
Without
With
+10.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
36 currently pending
Career history
1617
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
11.2%
-28.8% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
33.6%
-6.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1581 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-24 are pending in the instant application. Claims 11-20 and 22-24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. Claims 1-3, 8, 9, and 21 are rejected. Claims 4-7 and 10 are objected. Response to Amendment and Arguments/Remarks The amendment and arguments/remarks filed on December 12, 2025 have been fully considered and entered into the application. With regards to the 35 U.S.C. 102(a)(1) rejection as being anticipated by Levins et al., the grounds for rejection are moot in view of Applicant’s amendment and the rejection and objection have been withdrawn. However, this amendment has necessitated new grounds of rejection under 35 U.S.C. 102(a)(1), which are described below. New Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3, 8, 9, and 21 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Northrup et al. (J. Org. Chem. 2017, 82, 13020-13033). Northrup et al. discloses the compound 2, for example, and using it in a composition for the production of 5 (see Scheme 1 on page 13022). Therefore, a compound of the instant claims wherein R3 is hydrogen; R4 is alkyl; n and m are 1; R1 is a benzyloxycarbonyl protecting group (Cbz); and R2 is alkoxy and a composition thereof are anticipated by the reference. Claim Objections Claims 4-7 and 10 are objected to for depending on a previous rejected claim. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jun 14, 2022
Application Filed
Sep 27, 2023
Response after Non-Final Action
Aug 13, 2025
Non-Final Rejection — §102
Nov 13, 2025
Applicant Interview (Telephonic)
Nov 13, 2025
Examiner Interview Summary
Dec 12, 2025
Response Filed
Mar 16, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600712
AMINO-PYRIMIDINE AMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12600745
PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID
2y 5m to grant Granted Apr 14, 2026
Patent 12590094
COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS
2y 5m to grant Granted Mar 31, 2026
Patent 12590111
FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES
2y 5m to grant Granted Mar 31, 2026
Patent 12590093
INDOLO[2',3':3,4]PYRIDO[2,1-B]QUINAZOLINE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.5%)
2y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 1581 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month